Tag: Skin Disorders: Misc.
Reactions appeared near injection site at a median onset of day 8 after first dose; six of 12 patients had no recurrence after second dose
Cutaneous findings varied among patients; annular plaques in the proximal medial lower extremities were common
Significantly more patients treated with tirbanibulin had complete clearance of lesions at day 57
Patients report telehealth consultations are safe and efficient during the COVID-19 pandemic
Findings based on systematic clinical, histologic, and biologic assessment
Treating, monitoring irritated skin may prevent pressure injuries
Papulosquamous eruptions, pernio/chilblains last ≥60 days in some patients